Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21231
- Sidney Kimmel Cancer Center @ Johns Hopkins
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Histologically confirmed metastatic or unresectable solid tumor which standard curative or palliative measures do not exist or are no longer effective. The primary site of the metastatic or unresectable tumor must have arisen within a previously irradiated site and be considered a radiation-induced tumor.
- Pre-treatment tumor specimen available. Patients with no available archived specimen must be willing to undergo a pre-treatment tumor biopsy.
- Measurable disease.
- Progressive disease on study entry.
- Received adjuvant or neoadjuvant chemotherapy and developed recurrent or metastatic disease within 6 months of completing therapy.
- Age >18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status <2.
- Life expectancy of greater than 3 months.
- Adequate organ and marrow function as defined below:
- White Blood Cell >2,000/per microliter
- Absolute neutrophil count >1,500/per microliter
- Platelets >100,000/per microliter
- Hemoglobin ≥9.0 g/dL
- Total bilirubin ≤1.5 times the institutional upper limit of normal (ULN) (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
- Aspartate Aminotransferase(SGOT)/Alanine Aminotransferase (SGPT) <3 X institutional ULN
- Creatinine ≤1.5 X institutional ULN OR
- Creatinine clearance >40 mL/min for patients with creatinine Levels above institutional normal (calculated using the Cockcroft-Gault formula below)
- Female Creatinine Clearance = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL
- Male Creatinine Clearance = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in mg/dL
- Women of childbearing potential (WOCBP) and men must agree to use adequate contraception prior to study entry and for the duration of study participation and up to 31 weeks after the last dose of nivolumab.
- Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 24 hours prior to the start of nivolumab.
- Ability to understand and the willingness to sign a written informed consent document.
- Biopsiable disease at the time of enrollment as biopsies after progression are required for participation.
Exclusion Criteria:
- Any active, known or suspected autoimmune disease.
- Requiring continuous supplemental oxygen.
- Chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or unresolved toxicity due to agents administered more than 2 weeks earlier.
- Uncontrolled brain metastases.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab.
- Uncontrolled inter-current illness.
- Pregnant or currently breastfeeding.
- Receiving any other anticancer therapy.
- Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA- 4 antibody therapies, any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways.
- History of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
- Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating ongoing acute or chronic infection.
- Requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of study drug administration.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Radiation-Induced Metastatic Sarcoma
a flat dose of Nivolumab 240 mg will be administered intravenously every 2 weeks until disease progression.
|
Altri nomi:
|
|
Sperimentale: Radiation-Induced Non-Sarcoma Metastatic Solid Tumors
a flat dose of Nivolumab 240 mg will be administered intravenously every 2 weeks until disease progression.
|
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Best Objective Response Rate
Lasso di tempo: Up to 24 weeks
|
Number of participants with response.
Response will be assessed at baseline (within 4 weeks prior to starting nivolumab) and then every 8 weeks while on Nivolumab, up to 24 weeks.
The best objective response will be assessed at 24 weeks.
Response will be defined based on RECIST 1.1 criteria where complete response (CR)= disappearance of all target lesions, partial response (PR) is =>30% decrease in sum of diameters of target lesions, progressive disease (PD) is >20% increase in sum of diameters of target lesions, stable disease (SD) is <30% decrease or <20% increase in sum of diameters of target lesions.
|
Up to 24 weeks
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of Patients Progression-free at 24 Weeks From the Time of Enrollment
Lasso di tempo: 24 weeks
|
Disease status at 24 weeks will be compared to disease status at the time of enrollment, and response coded based on RECIST 1.1 criteria.
|
24 weeks
|
|
Progression-free Survival
Lasso di tempo: Up to 22 months
|
Number of participants alive without progression.
|
Up to 22 months
|
|
Duration of Response
Lasso di tempo: Up to 22 months
|
The duration of overall response is measured from the time measurement criteria are met for Complete Response or Partial Response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, accessed up to 3 years.
|
Up to 22 months
|
|
Number of Participants With Treatment-related Adverse Events
Lasso di tempo: up to 100 days post-intervention
|
Number of participants with treatment-related adverse events as defined by CTCAE 4.0 criteria.
|
up to 100 days post-intervention
|
|
Overall Survival
Lasso di tempo: Up to 22 months
|
Overall survival was planned to be measured at 5 years post-intervention as the time from enrollment until death.
Instead, due to early termination for low accrual, the number of participants alive at the time of study termination is reported.
|
Up to 22 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Patrick Forde, MB, BCH, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Studiare le date dei record
Studia le date principali
Inizio studio
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- J1695
- IRB00105682 (Altro identificatore: JHMIRB)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .